Primary hepatic neuroendocrine tumour with multiple liver metastases: A case report with literature review

Wei-Ming Yu; Ri Li; Bing-Lun Sun; Ji-Kang Du; Hong-Fang Tuo

doi:10.1016/j.ijscr.2021.106590

Primary hepatic neuroendocrine tumour with multiple liver metastases: A case report with literature review

Int J Surg Case Rep. 2021 Dec:89:106590. doi: 10.1016/j.ijscr.2021.106590. Epub 2021 Nov 12.

Authors

Wei-Ming Yu¹, Ri Li¹, Bing-Lun Sun¹, Ji-Kang Du¹, Hong-Fang Tuo²

Affiliations

¹ Graduate School of North China University of Science and Technology, Tangshan 063210, Hebei Province, China; Department of Hepatobiliary Surgery, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China.
² Department of Hepatobiliary Surgery, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China. Electronic address: ywmhcg@163.com.

Abstract

Introduction and importance: To describe an unusual case with a primary hepatic neuroendocrine tumour (PHNET) with multiple liver metastases.

Case presentation: We reported a 65-year-old woman with PHNET with multiple liver metastases. She was highly suspected of having primary liver cancer with multiple intrahepatic metastases before liver biopsy, but was diagnosed with PHNET with multiple liver metastases after histopathology and immunohistochemistry (IHC) examinations. The patient successfully underwent three times of transcatheter arterial chemoembolization (TACE), and is currently living in a good state without related complications.

Clinical discussion: Neuroendocrine tumors (NETs), also known as carcinoids or argyrophilic tumors, are very rare malignant tumors. The liver is the main metastasis site of NETs, but primary hepatic neuroendocrine tumors (PHNETs) are extremely rare. Histopathology and immunohistochemistry (IHC) examinations are still the main methods used for diagnosing NETs. There are no treatment guidelines for PHNETs, and surgical resection is generally the preferred treatment. For PHNET patients who are not suitable for surgery, TACE has been proven to be an effective alternative treatment that can effectively reduce the tumour burden and relieve symptoms, but the current evidence is still limited.

Conclusion: The clinical diagnosis of PHNET still faces great challenges, imaging examinations often lead to misdiagnosis, and its diagnosis mainly depends on histopathology and immunohistochemical examinations. For PHNET patients who are not suitable for surgery, TACE may be an effective alternative therapy.

Keywords: Case report; Immunohistochemistry; Liver metastasis; Neuroendocrine tumour; Primary hepatic neuroendocrine tumour; Transcatheter arterial chemoembolization.